Ascendis Pharma A/S
NASDAQ:ASNDBiotechnology
-$0.05 today
- Market cap
- $17.73B
- Beta
- 0.39
- P/E (TTM)
- 24.5
- EPS (TTM)
- $8.21
Volume 0.57M
Average 0.64M
ASND Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Ascendis Pharma A/SNASDAQ: ASND
Free Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Free cash flow growth accelerates
Q3 FY2026 free cash flow of €182.07M rose 8570.1% year over year, ahead of the +560.9% change in trailing-twelve-month free cash flow. Sequentially, it fell 35.7% from the prior quarter.
Context
- Free cash flow amounted to 6.3% of revenue in FY2025, down 78.3 pp from a year earlier.
- Free cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +8570.1% holds above the trailing-twelve-month pace of +560.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
EUR · from the cash flow
- Latest · FY2025
- 43.62M EUR
- Year-over-year change
- +114.2%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 43.62M | +114.2% |
| FY2024 | 2024-12-31 | (307.62M) | +34.5% |
| FY2023 | 2023-12-31 | (469.8M) | +7.9% |
| FY2022 | 2022-12-31 | (510.19M) | -15.5% |
| FY2021 | 2021-12-31 | (441.88M) | — |
Free Cash Flow vs competitors
How ASND compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +560.9% is the 2nd highest of 11, against a peer median of +10.0%.
- Free cash flow amounts to 42.8% of revenue for ASND, versus a peer median of 48.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $499B USD | +60307.4% | +136.3% | 48.6% | |
| LTM Jun 2026 | $1.09B USD | +2.1% | +16.2% | 34.6% | |
| LTM Sep 2026 | $1.04B USD | +75.3% | +32.4% | 28.1% | |
| LTM Jun 2026 | $837.67M USD | -3.6% | +33.1% | 73.6% | |
| LTM Sep 2026 | €516.87M EUR | +560.9% | — | 42.8% | |
| LTM Mar 2026 | $487.2M USD | +18.0% | -3.6% | 72.8% | |
| LTM Mar 2026 | $147.7M USD | -313.4% | — | 460.4% | |
| LTM Jun 2026 | $106.92M USD | -40.7% | +5.7% | 12.9% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $99.33M USD | +25.9% | +51.5% | — |
SEPNSepterna, Inc. | LTM Sep 2026 | $77.59M USD | -175.2% | — | 80.6% |
| LTM Mar 2026 | $47.23M USD | +272.2% | — | 15.0% | |
| Peer median (excluding ASND) | — | +10.0% | +32.4% | 48.6% | |
Competitors are the stored peer set for ASND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (383.58M) | (583.19M) | (481.45M) | (378.08M) | (219.03M) |
| Depreciation & Amortization | 15.39M | 17.96M | 18.91M | 17.71M | 17M |
| Deferred Income Tax | (367K) | 5.38M | 7.3M | 4.84M | 3.21M |
| Stock-Based Compensation | 66.83M | 64.18M | 66.66M | 95.51M | 0 |
| Change in Working Capital | (47.72M) | (12.47M) | (99.79M) | (107.16M) | 68.16M |
| Accounts Receivables | (6.66M) | (11.53M) | (32.77M) | (118.61M) | 14.97M |
| Inventory | (75.41M) | (55.27M) | (78.26M) | (86.68M) | (5.69M) |
| Accounts Payables | 0 | 0 | 0 | 0 | (9.96M) |
| Other Working Capital | 34.34M | 54.33M | 11.25M | 98.13M | 68.84M |
| Other Non-Cash Items | (68.21M) | 12.45M | 21M | 60.98M | 182.44M |
| Operating Cash Flow | (417.65M) | (495.7M) | (467.36M) | (306.2M) | 51.77M |
| Capital Expenditures | (24.23M) | (14.49M) | (2.44M) | (1.43M) | (8.15M) |
| Acquisitions (Net) | (10.19M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (226.04M) | (213.84M) | 0 | 0 | 0 |
| Sales of Investments | 149.88M | 280.53M | 0 | 7.35M | 0 |
| Other Investing Activities | (530K) | 9.54M | 288.92M | 950K | 0 |
| Investing Cash Flow | (110.58M) | 61.73M | 286.47M | 6.88M | (8.15M) |
| Debt Repayment | (6.43M) | 496.93M | 125.82M | 122.79M | (21.09M) |
| Common Stock Issued | 367.88M | 0 | 0 | 309.91M | 83.64M |
| Common Stock Repurchased | (21.61M) | (105.31M) | (1.81M) | 0 | (16.71M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 11.54M | 5.15M | 10.29M | 11.22M | (10.95M) |
| Financing Cash Flow | 351.39M | 396.77M | 134.29M | 443.93M | 34.89M |
| Effect of Forex Changes | 38.59M | 35.69M | (6.01M) | 22.77M | 44.13M |
| Net Change in Cash | (138.25M) | (1.5M) | (52.6M) | 167.38M | 122.65M |
| Free Cash Flow | (441.88M) | (510.19M) | (469.8M) | (307.62M) | 43.62M |
Ascendis Pharma A/S
NASDAQ:ASND
Intrinsic Alpha fair value
Locked
Current Price
$270.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.